Stock comparison
JOHNSON & JOHNSON is 1.4x more valuable than AbbVie Inc. by market capitalization ($622.64 B vs $440.14 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
JNJ is larger
JOHNSON & JOHNSON is 1.4x more valuable than AbbVie Inc. by market capitalization ($622.64 B vs $440.14 B).
Market value leader
JNJ
JOHNSON & JOHNSON is 1.4x more valuable than AbbVie Inc. by market capitalization ($622.64 B vs $440.14 B).
Revenue leader
JNJ
JNJ: $94.19B vs ABBV: $61.16B.
Profit leader
JNJ
JNJ: $26.80B vs ABBV: $4.23B.
Margin leader
JNJ
JNJ: 28.5% vs ABBV: 6.9% net margin.
| Metric | JNJ | ABBV |
|---|---|---|
| Market cap | $622.64 B | $440.14 B |
| US-listed rank | #18 | #25 |
| Revenue (latest FY) | $94.19B | $61.16B |
| Net income (latest FY) | $26.80B | $4.23B |
| Net margin | 28.5% | 6.9% |
| P/E (trailing FY) | 23.2x | 104.2x |
| SEC filings | 990 | 1,008 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
JOHNSON & JOHNSON is 1.4x more valuable than AbbVie Inc. by market capitalization ($622.64 B vs $440.14 B).
In their latest fiscal years, JOHNSON & JOHNSON reported $94.19B in revenue while AbbVie Inc. reported $61.16B.
Full pages: JOHNSON & JOHNSON and AbbVie Inc., or browse the full rankings.